• Citer

Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors.

par Stahel, R A;Sculier, Jean-Paul ;Jost, L M;Delforge, Alain ;Bron, Dominique ;Gmür, J;Oelz, O;Sauter, C;Stryckmans, Pierre ;Klastersky, Jean
Référence European journal of cancer & clinical oncology, 25, 6, page (965-972)
Publication Publié, 1989-06

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors.
Auteur:	Stahel, R A; Sculier, Jean-Paul; Jost, L M; Delforge, Alain; Bron, Dominique; Gmür, J; Oelz, O; Sauter, C; Stryckmans, Pierre; Klastersky, Jean
Informations sur la publication:	European journal of cancer & clinical oncology, 25, 6, page (965-972)
Statut de publication:	Publié, 1989-06
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Aged
	Carcinoma, Renal Cell -- secondary
	Carcinoma, Renal Cell -- therapy
	Drug Evaluation
	Drug Tolerance
	Female
	Humans
	Interleukin-2 -- adverse effects
	Interleukin-2 -- therapeutic use
	Kidney Neoplasms
	Killer Cells, Natural
	Leukapheresis
	Lymphocyte Activation
	Male
	Middle Aged
	Neoplasms -- therapy
	Recombinant Proteins -- adverse effects
	Recombinant Proteins -- therapeutic use
Note générale:	Journal Article
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0277-5379
	info:doi/10.1016/0277-5379(89)90155-7
	info:pii/0277537989901557
	info:scp/0024380062
	info:pmid/2787749